Key result
Doxorubicin chemotherapy increased serum cTnI concentrations in dogs compared to baseline, with elevations preceding clinical signs in those developing cardiomyopathy.
Why the study?
Does doxorubicin chemotherapy increase serum cTnI concentrations in dogs with lymphoma or osteosarcoma, and does it predict cardiomyopathy?
Observational
Does doxorubicin chemotherapy increase serum cTnI concentrations in dogs with lymphoma or osteosarcoma, and does it predict cardiomyopathy?
In dogs receiving doxorubicin, serum cTnI concentrations increase following chemotherapy and may serve as an early biomarker for the subsequent development of cardiomyopathy.
Answers are grounded in this paper and cite their sources.
cTnI rises may flag early cardiotoxicity risk in doxorubicin-treated dogs; leaves open whether monitoring improves outcomes in prospective trials.
The cumulative cardiotoxicity that occurs as a result of doxorubicin chemotherapy is irreversible and can affect both quality and quantity of life for the cancer patient. Cardiac troponin I (cTnI) is a sensitive and specific marker of cardiomyocyte death. The purpose of this retrospective study was to evaluate serum concentrations of cTnI in dogs with lymphoma or osteosarcoma given doxorubicin chemotherapy, and with known cardiac outcome, based on a minimum assessment by physical examination and thoracic radiography. Serum samples were also available for cTnI measurement from seven healthy dogs given intracoronary doxorubicin. Serial serum samples obtained before, during and after doxorubicin chemotherapy showed increased cTnI concentrations in some clinical patients following chemotherapy (P = 0.0083 compared to baseline), but this did not correlate with clinical signs of cardiomyopathy. In dogs that subsequently developed cardiomyopathy however, serum cTnI concentrations were elevated before clinical signs became evident (confirmed with echocardiography).
No takes yet. Share an insight, caveat, or question.
Selting et al. (2004) conducted an observational in Lymphoma and osteosarcoma in dogs. Doxorubicin chemotherapy vs. Baseline was evaluated on Serum concentrations of cTnI (p=0.0083). Doxorubicin chemotherapy increased serum cTnI concentrations in dogs compared to baseline, with elevations preceding clinical signs in those developing cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: